



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
AUG 09 2002
TECH CENTER 1600/2900

Applicant: **Gruenberg, M.**

Serial No.: **09/824,906**

Conf. No. **9764**

Filed: **April 2, 2001**

For: **AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE**

Art Unit: **1644**

Examiner: **Schwadran, R.**

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV18332197US

Date of Deposit August 5, 2002

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed to:
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Alicia Bradbury 8/5/02

Alicia Bradbury

Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. § 1.97-1.98**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed before receipt of a First Office Action on the merits for the above-captioned application, no fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) is provided herewith in connection with the above-captioned application. In accordance with 37 C.F.R. §1.98(d), copies of the references listed on the Form PTO-1449 which have been previously provided in connection with applications U.S. Serial No. 08/700,565 which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120, are not provided herewith.

U.S.S.N. 09/824,906
GRUENBERG
Supplemental IDS

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing reference and it be made of record in the file history of the above-captioned application.

* * *

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24731-500G
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-500GSERIAL NO.
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERG, M.FILING DATE
April 2, 2001GROUP
1644

AUG 09 2002

RECEIVED
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	5	1	2	3	9	0	1	06/23/92	Carew	604	5	
	B	5	6	3	7	4	8	1	06/10/97	Ledbetter <i>et al.</i>	435	69.6	09/13/93
	C	5	7	6	6	9	2	0	06/16/98	Babbit <i>et al.</i>	435	240.1	06/06/95
	D	5	8	5	8	3	5	8	01/12/99	June <i>et al.</i>	424	130.1	06/03/94
	E	5	9	9	4	1	2	6	11/30/99	Steinman <i>et al.</i>	435	325	06/17/94

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
	F	2	8	8	3	2	0	1	04/99	JP B2			claims

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	G	Certified English language translation of the Japanese Patent No. 2883201.
	H	Derwent #008306271 WPI Acc. No. 1990-193272/199025 (citing, WO Patent Publication WO90/05541, the parent of Japanese Patent Publication No. JP 2883201, published April 19, 1999).
	I	June <i>et al.</i> , "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", <i>Molecular and Cell Biology</i> , Dec: 4472-4481 (1987).
	J	Martin <i>et al.</i> , "A 44 Kilodalton Cell Surface Homodimer Regulates Interleukin 2 Production By Activated Human T Lymphocytes", <i>J. of Immunol.</i> 136(9): 3282-3287 (1986).
	K	Nabel <i>et al.</i> , An inducible transcription factor activates expression of human immunodeficiency virus in T cells, <i>Nature</i> , 326:711-3, (1987).
	L	Translation (not certified) of the Claims for the Japanese Patent No. 2883201.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.